{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000024","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.726215+00:00","generated_at":"2026-05-24T12:50:46.400964+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M","bullets":["Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.","No further royalty due from January 1, 2025 forward; buyout covers all future net revenues.","Funded with cash on hand; enhances financial flexibility for Retina portfolio growth.","CEO Nikhil Lalwani states the transaction reflects commitment to maximizing long-term value of ILUVIEN and YUTIQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000024","json":"https://secwatch.observer/filing/0001023024-25-000024.json","markdown":"https://secwatch.observer/filing/0001023024-25-000024.md","text":"https://secwatch.observer/filing/0001023024-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/0001023024-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/ani-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:50:46.400964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}